Table 1.

Selected all-grade adverse events associated with the targeted agents sunitinib, sorafenib, bevacizumab/IFN-α, temsirolimus, everolimus, and pazopanib, approved in Europe and/or the United States for the treatment of metastatic RCC

Adverse event (%)	Sunitinib	Sorafenib	Bevacizumab plus IFN-α	Temsirolimus	Everolimus	Pazopanib
Anorexia	34	16	36	32	16	22
Asthenia	20	—	32	51	18	14
Diarrhea	61	43	20	27	17	52
Dyspnea	10	14	13	28	8	—
Fatigue	54	37	33	—	20	19
Hand–foot syndrome	29	30	—	—	—	—
Hyperglycemia	—	—	—	26	50	41
Proteinuria	—	—	18	—	—	—
Hypertension	20	17	26	—	—	40
Anemia	79	8	10	45	91	—
Lymphopenia	68	—	—	—	42	31
Neutropenia	77	—	7	7	11	34
Thrombocytopenia	68	—	6	14	20	32
Leucopenia	78	—	—	6	26	32
Discontinuations due to AEs (%)	19	10	28	7	10	NR

NOTE: Data from refs. 6, 64–68.

Abbreviations: AE, adverse event; NR, not reported.